Market Place
Sourcing Support
Storm Therapeutics Presents Data on METTL3 Inhibitor at SITC
11 Nov 2024 //
PR NEWSWIRE
STORM`s METTL3 Inhibitor STC-15 Interim Phase 1 Data At ASCO
03 Jun 2024 //
PR NEWSWIRE
STORM`s to Present Ph1 Data on its METTL3 RNA Methyltransferase Inh. STC-15
24 May 2024 //
PHARMIWEB
Storm Stc-15 Interim Phase 1: Asco 2024 Mettl3 Rna Methyltransferase
24 May 2024 //
PR NEWSWIRE
STORM to Present Data on its First-in-Class METTL1 tRNA Methyltransferase Inb
26 Mar 2024 //
PR NEWSWIRE
STORM Therapeutics Appoints Marguerite Hutchinson as Chief Business Officer
01 Nov 2023 //
PR NEWSWIRE
STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15
17 Oct 2023 //
PR NEWSWIRE
STORM publishes in Cancer Discovery showing induction of anti-tumour immunity
08 Aug 2023 //
PR NEWSWIRE
Storm Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML
25 Jan 2023 //
PR NEWSWIRE
Storm reveals STC-15 data for patients with acute myeloid leukaemia
25 Jan 2023 //
PHARMATIMES
Storm doses first patient with solid tumour drug candidate
24 Nov 2022 //
PHARMATIMES
STORM Therapeutics doses first patient with oral METTL3
23 Nov 2022 //
PRNEWSWIRE
STORM to present new data on its lead program STC-15 at SITC
20 Oct 2022 //
PRNEWSWIRE
STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer
07 Sep 2022 //
PRNEWSWIRE
STORM Therapeutics Awarded Innovate UK Grant for Novel Coronavirus Therapy
03 May 2022 //
PRNEWSWIRE
Exelixis and STORM Collaborate for Inhibitors of Novel RNA Modifying Enzymes
14 Oct 2021 //
BUSINESSWIRE
Data published on novel molecules for leukaemia treatment
26 Apr 2021 //
PHARMAFILE
STORM publishes data in Nature showing its first-in-class inhibitor of METTL3
26 Apr 2021 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.